Arvinas (ARVN) in Pivotal Point Check: Groundbreaking PROTAC Drugs and Analyst Upgrade Drive Biotech Company Up Over 20% After Quarterly Results!
Reading Time: 2 minutes
Arvinas is developing a new class of drugs called PROTAC to selectively degrade disease-causing proteins. The focus is on developing therapies in the fields of oncology (cancer) and neuroscience. Stephens raised the price target considering the quarterly earnings released shortly before. Arvinas is a clinical-stage biotechnology company. The company is developing a new class of oral medications known as PROTACs (PROteolysis TArgeting Chimeras). What sets PROTAC drugs apart is that they utilize the body's natural protein disposal system...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
